Remove Biotechnology Remove Licensing Remove Programming
article thumbnail

Mars Society gains foothold in AI, robotics and biotechnology to clear a path to space

GeekWire

A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.

article thumbnail

Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics

GeekWire

Sana Biotechnology has a new $50 million tool in its toolbox. Gene editing technology is a key component in developing engineered cells as medicines, and we are pleased to have the ability to use the Cas12b system as part of a number of our ex vivo engineered cell programs,” said Steve Harr , Sana’s president and CEO in a statement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M

GeekWire

Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome.

article thumbnail

Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger

GeekWire

The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Seattle biotech company Good Therapeutics sold its IL-2 program to Roche for $250 million in September and later rebranded as Bonum Therapeutics.

article thumbnail

Merck’s multi-billion dollar bet on Seattle Genetics sparks hope for breast cancer treatments

GeekWire

based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo). Merck will own about 2.9

article thumbnail

Tech Moves: Seattle tech vet named CEO at Vouched; Sana hires chief scientific officer

GeekWire

Founded in 2018, Vouched helps companies verify the identity of customers and users by examining driver’s licenses and other forms of identification. Sana Photo) — Dhaval Patel joined Sana Biotechnology as executive vice president and chief scientific officer. It can provide fraud detection of a person in real-time.

article thumbnail

Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases

GeekWire

The UW has licensed the exclusive rights of this intellectual property to the startup. This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program,” Daggett said in a statement.